Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran 1333625445, Iran; Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran 1333625445, Iran.
Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran 1996835113, Iran.
Int Immunopharmacol. 2021 Aug;97:107707. doi: 10.1016/j.intimp.2021.107707. Epub 2021 Apr 21.
Since late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, better known as COVID-19) has rapidly spread worldwide. The primary pathophysiology by which COVID-19 leads to severe lung damage is cytokine releasing syndrome (CRS), which can cause death. Therefore, removing cytokines via therapeutic plasma exchange or hemoperfusion could be a therapeutic approach to treat CRS. However, hemoperfusion or therapeutic plasma exchange could alter the effectiveness of concomitant medications. Thus, concomitant medication doses might need to be adjusted to prevent their elimination via therapeutic plasma exchange or hemoperfusion, thus ensuring that these medications remain effective. This narrative review investigates the elimination status of current medications used to manage COVID-19 during hemoperfusion and therapeutic plasma exchange, with a focus on their pharmacokinetic profiles.
自 2019 年末以来，严重急性呼吸综合征冠状病毒 2（SARS-CoV-2，俗称 COVID-19）在全球范围内迅速传播。COVID-19 导致严重肺部损伤的主要病理生理学机制是细胞因子释放综合征（CRS），这可能导致死亡。因此，通过治疗性血浆置换或血液灌流清除细胞因子可能是治疗 CRS 的一种治疗方法。然而，血液灌流或治疗性血浆置换可能会改变伴随药物的疗效。因此，可能需要调整伴随药物的剂量，以防止通过治疗性血浆置换或血液灌流消除这些药物，从而确保这些药物保持有效。本叙述性综述探讨了在血液灌流和治疗性血浆置换过程中，用于治疗 COVID-19 的当前药物的消除状态，重点关注其药代动力学特征。
